MEDICAL RECORD 
CONTINUATION SHEET for either: 
STUDY NUMBER: 
CONTINUATION: page i_of 14 pages. 
cells in the bone marrow to <5% may have very prolonged 
disease remissions. If a patient with a complete response to 
interferon later develops return of Philadelphia chromosome 
positive cells, she/he will become a candidate for the rest 
of this protocol. 
Patients that do not achieve a reduction in Philadelphia 
chromosome positive cells to <5% after one year of interferon 
treatment or do not lower their white blood cell count 
adequately on interferon will proceed onto the next step in 
the protocol. Interferon will be stopped for at least one 
month before starting the next treatment step. 
Recombinant Interferon Alpha is a human protein that can be 
produced for medical uses in large quantities in bacteria or 
yeast. It may cause low blood counts, flu-like symptoms such 
as fever, fatigue, headache, chills and achy muscles, nausea, 
vomiting, loss of appetite, diarrhea, dizziness, numbness in 
fingers and toes, temporary impotence, skin rash, and hair 
loss. In rare instances, confusion, depression, visual 
disturbances, sleep disturbances, nervousness, and heart 
problems which include high blood pressure, chest pain, and 
irregular heart beat may occur. 
Group 2 Patients only (> 1st chronic phased : 
1) . No Interferon treatment will be given. 
Both Groups 1 and 2 : 
2) . High-dose chemotherapy: You will be given one intravenous 
infusion of the chemotherapeutic drug Daunorubicin. The 
same day you will begin a continuous intravenous infusion of 
a second chemotherapeutic drug called Cytarabine that will 
be continued for a total of four days. Treatment may be 
repeated for patients in blast crisis (Group 2) who fail to 
achieve a complete remission with one cycle. Some blast 
phase patients (Group 2) may instead be treated with two 
different drugs called vincristine and prednisone if the 
abnormal blast cells in their blood and bone marrow are 
lymphocytes (a certain type of white blood cell). 
You will be given these chemotherapeutic drugs in an attempt 
WENT IDENTIFICATION 
CONTINUATION SHEET for either: 
Recombinant DNA Research, Volume 16 
[183] 
